MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$970,972
EPS
-$0.03
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
General and administrative
1,136,709 328,510* 1,754,856
Research and development
109,434 -210,527* 158,699
Total operating expenses
1,246,143 117,983 1,913,555
Loss from operations
-1,246,143 -117,983* -1,913,555
Net gain from change in fair value of derivative liability instrument
697,561 2,487,591.5* -
Gain from change in fair value of forward contract liability
--95,110.5* -
Amortization of deferred offering cost
477,647 124,237* -
Interest income
49,679 14,250* 5,111
Other income
5,578 163,740* 4,260
Total other income
275,171 2,636,455* 9,371
Net gain
-970,972 2,518,472 -1,904,184
Basic EPS
-0.03 0.092 -0.07
Diluted EPS
-0.03 0.092 -0.07
Basic Average Shares
29,476,002 27,456,883 27,975,207
Diluted Average Shares
29,476,002 27,456,883 27,975,207
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net gain from changein fair value of...$697,561 Interest income$49,679 Other income$5,578 Net gain-$970,972 Total other income$275,171 Amortization of deferredoffering cost$477,647 Loss from operations-$1,246,143 Total operatingexpenses$1,246,143 General andadministrative$1,136,709 Research and development$109,434

Turn Therapeutics Inc. (TTRX)

Turn Therapeutics Inc. (TTRX)